2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings. The author explores the data around their post-IPO share performance, relative to prior years.
Category: NASDAQ:AGIO
Jackie Fouse, Admired By Investors, To Become CEO Of Biotech Agios
“It’s a fabulous company and it’s at a perfect stage of its life cycle,” Fouse says. She notes that Agios has spent a decade proving itself, and now has two approved products.
